Mavixen (Glecaprevir + Pibrentasvir) Tablets
Mavixen (Glecaprevir 100 mg + Pibrentasvir 40 mg) is a fixed-dose combination generic of Mavyret, offering a pan-genotypic cure for Hepatitis C.
Manufacturer: Everest Pharmaceuticals. Each bottle contains 21 tablets (a 1-week supply). It contains two distinct antiviral agents that target the virus at different stages of its life cycle.
Key Advantages:
1. ⚡ Short Course: It offers the shortest treatment duration available—typically just 8 weeks for most patients without cirrhosis.
2. 🛡️ Renal Safety: It is the preferred regimen for patients with severe kidney impairment, including those on dialysis.
✅ Benefit: High cure rates (>98%) across all genotypes (1–6).
Indicated for the treatment of chronic Hepatitis C (CHC) in adults and adolescents:
- 🦠 Pan-Genotypic: Approved for Genotypes 1, 2, 3, 4, 5, and 6.
- 🏥 Renal Impairment: Safe for use in patients with any degree of renal impairment (CKD).
- 💊 Retreatment: Effective for patients who have failed prior treatments (DAA-experienced).
Packaging: 21 tablets per bottle (1-week supply).
⚠️ ADMINISTRATION PROTOCOL:
- 💊 Dose: Take 3 tablets at once, once daily. Total daily dose: 300 mg Glecaprevir / 120 mg Pibrentasvir.
- 🍔 With Food: Must be taken with food to ensure proper absorption.
- 📅 Duration: Standard course is 8 weeks (8 bottles). Duration may be 12 or 16 weeks for patients with cirrhosis or specific prior treatment failures.
- Severe hepatic impairment (Child-Pugh C).
- Co-administration with Atazanavir or Rifampin.
- Pregnancy and breastfeeding.
- Use of ethinyl estradiol-containing contraceptives (may increase liver enzymes).
Mavixen is generally well-tolerated. Common adverse reactions include:
- 🤯 Neurological: Headache.
- 💤 General: Fatigue.
- 🤢 Gastrointestinal: Nausea (mitigated by taking with food).
- Pruritus (itching) is rare but possible.
What Customers Say
No reviews yet
Your review can be the first!